Investing.com - Financial Markets Worldwide

Oric Pharmaceuticals director You Angie buys $262,898 in stock

Published 24/06/2025, 01:20
Oric Pharmaceuticals director You Angie buys $262,898 in stock
ORIC
-0.43%

Director You Angie of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) recently purchased a total of $262,898 in company stock. According to a Form 4 filing with the Securities and Exchange Commission, the purchases were made in two transactions at prices ranging from $9.3871 to $9.43 per share. The stock, currently trading at $10, appears overvalued according to InvestingPro Fair Value metrics, despite showing strong returns of over 30% in the past year.

On June 20, 2025, You Angie acquired 26,597 shares of Common Stock. The price range for this transaction was between $9.14 and $9.50, with a weighted average price of $9.3871.

Then, on June 23, 2025, You Angie bought another 1,403 shares at $9.43 per share. Following these transactions, You Angie directly owns 28,000 shares of Oric Pharmaceuticals.

In other recent news, ORIC Pharmaceuticals announced promising preliminary results from its Phase 1b trial of ORIC-944, in combination with AR inhibitors, for metastatic castration-resistant prostate cancer. The trial showed a 59% PSA50 response rate and a 24% PSA90 response rate, with most adverse events being mild to moderate. These findings have been highlighted by H.C. Wainwright, which maintained a Buy rating with a $22.00 price target. Cantor Fitzgerald also reiterated an Overweight rating, citing the drug’s potential in the prostate cancer market.

Additionally, ORIC Pharmaceuticals secured $125 million through a private placement, expected to extend its cash runway into the second half of 2027. This financial boost supports the company’s ongoing research and development, including the anticipated Phase 3 trial of ORIC-944. The company continues to explore dose options and plans to initiate a global Phase 3 registrational trial in the first half of 2026. Investors are closely watching these developments, as ORIC Pharmaceuticals advances its clinical trials and research programs in the oncology field.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.